Teva Pharmaceuticals' Request to Delay Paragard Lawsuit Trial Denied by Judge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Should l Buy COO?
Source: Benzinga
- Trial Progress: A Georgia federal judge denied Teva Pharmaceuticals' request to delay the Paragard IUD lawsuit trial, ruling that it will proceed on January 20, 2024, marking the first trial in approximately 3,800 lawsuits, which could significantly impact the company's future legal liabilities and financial outlook.
- Litigation Context: Plaintiffs allege that the Paragard device can fracture during removal, leading to injuries and fertility complications, while Teva argues that FDA approval should preempt state law claims, indicating the company's urgency in its legal strategy to appeal for dismissal of the claims.
- Compliance Issues: The judge expressed concern over Teva's five-year delay in updating Paragard's warning labels as mandated by the FDA in 2010, suggesting potential intentionality that could undermine the court's trust in Teva and affect the case's outcome, thereby increasing the company's legal risks.
- Market Reaction: Teva's stock fell 0.21% to $32.72 in the latest trading session, reflecting market concerns about the upcoming trial and its potential financial implications, which may lead to decreased investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COO
Wall Street analysts forecast COO stock price to rise
12 Analyst Rating
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 83.670
Low
73.00
Averages
90.33
High
100.00
Current: 83.670
Low
73.00
Averages
90.33
High
100.00
About COO
The Cooper Companies, Inc. is a global medical device company. The Company operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. It also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Key Companies to Monitor This Week: Jobs, CrowdStrike, Target, Broadcom, Costco, and Others
- Stock Market Performance: The S&P 500 index fell by 0.4% last week, marking a 0.9% decline for February, which is only the second monthly drop since April.
- Trading Range: The S&P 500 has been trading within a narrow range this year, with a low of approximately 6800 and a high of around 7000.
See More
Job Report Outlook Uncertain Amid Rising AI Impact
- Inflation Pressures Rise: The latest wholesale inflation report indicates that markets have underestimated pricing pressures, leading to a more than 600-point drop in the Dow Jones Industrial Average, reflecting heightened investor concerns about the economic outlook that could impact future interest rate policies.
- Job Market Expectations: The U.S. economy is expected to add 60,000 jobs in February, with the unemployment rate holding steady at 4.3%, a figure significantly lower than last month's 130,000, indicating a market acceptance of a 'no hire, no fire' phenomenon, yet fears of AI's potential threat to employment are intensifying.
- Deepening AI Impact: Block's announcement of 4,000 layoffs to leverage AI automation led to a 24% surge in its stock price, but concerns about AI's potential to disrupt the economy have escalated, particularly affecting the software and real estate sectors.
- Uncertain Rate Outlook: Mizuho's chief economist anticipates payrolls of 100,000 in February, which could influence interest rate expectations; while the market currently prices in two rate cuts, he suggests the actual outcome may be zero, posing negative implications for the stock market.
See More
Insiders Invested Heavily in These 3 Stocks in Q4—One Shines Above the Rest
Insider Buying Trends: Insider buying was prominent in Q4 2025, particularly in three stocks, with one standout due to its simple and effective technology that is in high demand in a rapidly growing industry.
Stock Performance and Institutional Activity: Insiders, including directors, have been actively purchasing shares, accumulating about 2% of the stock, while institutions own around 24%, indicating strong market interest despite a decline in stock prices.
Market Sentiment and Short Interest: Short interest remains high at nearly 7%, contributing to stock price declines, but analysts suggest a potential rebound with a significant upside forecast of 200% relative to consensus targets.
Investment Recommendations: Analysts rate the stock as a moderate buy, with a minimum upside of 12%, indicating a favorable long-term outlook as the market stabilizes and improves in revenue and earnings.
See More
Teva Pharmaceuticals' Request to Delay Paragard Lawsuit Trial Denied by Judge
- Trial Progress: A Georgia federal judge denied Teva Pharmaceuticals' request to delay the Paragard IUD lawsuit trial, ruling that it will proceed on January 20, 2024, marking the first trial in approximately 3,800 lawsuits, which could significantly impact the company's future legal liabilities and financial outlook.
- Litigation Context: Plaintiffs allege that the Paragard device can fracture during removal, leading to injuries and fertility complications, while Teva argues that FDA approval should preempt state law claims, indicating the company's urgency in its legal strategy to appeal for dismissal of the claims.
- Compliance Issues: The judge expressed concern over Teva's five-year delay in updating Paragard's warning labels as mandated by the FDA in 2010, suggesting potential intentionality that could undermine the court's trust in Teva and affect the case's outcome, thereby increasing the company's legal risks.
- Market Reaction: Teva's stock fell 0.21% to $32.72 in the latest trading session, reflecting market concerns about the upcoming trial and its potential financial implications, which may lead to decreased investor confidence.
See More
Boyar Research Unveils 2026's 'Forgotten Forty' Stocks with High Upside Potential
- Undervalued Stocks: Boyar Research's 'Forgotten Forty' list includes stocks like Uber and Airbnb, which are expected to outperform the market in the coming year, reflecting renewed investor interest in value stocks.
- Tax Law Impact: Atlanta Braves Holdings faces a tax law change effective in 2027 that limits deductions for top executives, potentially reducing profitability and prompting owner John Malone to consider selling the team to mitigate tax implications.
- Market Potential: Markel Group, dubbed the 'baby Berkshire', is under activist pressure to unlock value through share buybacks and operational improvements, with a current share price around $2,000 and an estimated worth of $3,100, indicating strong growth potential.
- Business Split Expectations: Cooper Companies, with a 25% market share in contact lenses, is facing calls for a split to optimize capital allocation, which analysts believe will enhance overall business performance and drive stock price increases.
See More
CooperVision Launches MyDay® MiSight® 1 Day Contact Lenses for Myopia Control
- Market Expansion: CooperVision is set to launch MyDay® MiSight® 1 Day contact lenses in the UK and select European markets, aiming to meet the growing demand for myopia control by combining ActivControl® technology with modern silicone hydrogel materials, which is expected to significantly enhance the company's market share in pediatric vision correction.
- Technological Innovation: The new lenses utilize ActivControl® technology, which has been shown to reduce myopia progression by approximately 50%, providing more effective vision protection for millions of children and further solidifying CooperVision's leadership position in the eye care industry.
- Enhanced User Experience: The design of MyDay® MiSight® 1 Day lenses includes corrective and therapeutic zones, ensuring users achieve clear vision while effectively controlling myopia progression, which is anticipated to boost customer satisfaction and brand loyalty.
- Strategic Commitment: CooperVision's Commercial Director, Debbie Olive, stated that the company is unwavering in its commitment to addressing myopia both scientifically and commercially; the launch of this new product not only reflects technological advancement but also a long-term commitment to children's eye health, expected to drive future sales growth.
See More
Key Companies to Monitor This Week: Jobs, CrowdStrike, Target, Broadcom, Costco, and Others
- Stock Market Performance: The S&P 500 index fell by 0.4% last week, marking a 0.9% decline for February, which is only the second monthly drop since April.
- Trading Range: The S&P 500 has been trading within a narrow range this year, with a low of approximately 6800 and a high of around 7000.
See More
Job Report Outlook Uncertain Amid Rising AI Impact
- Inflation Pressures Rise: The latest wholesale inflation report indicates that markets have underestimated pricing pressures, leading to a more than 600-point drop in the Dow Jones Industrial Average, reflecting heightened investor concerns about the economic outlook that could impact future interest rate policies.
- Job Market Expectations: The U.S. economy is expected to add 60,000 jobs in February, with the unemployment rate holding steady at 4.3%, a figure significantly lower than last month's 130,000, indicating a market acceptance of a 'no hire, no fire' phenomenon, yet fears of AI's potential threat to employment are intensifying.
- Deepening AI Impact: Block's announcement of 4,000 layoffs to leverage AI automation led to a 24% surge in its stock price, but concerns about AI's potential to disrupt the economy have escalated, particularly affecting the software and real estate sectors.
- Uncertain Rate Outlook: Mizuho's chief economist anticipates payrolls of 100,000 in February, which could influence interest rate expectations; while the market currently prices in two rate cuts, he suggests the actual outcome may be zero, posing negative implications for the stock market.
See More
Insiders Invested Heavily in These 3 Stocks in Q4—One Shines Above the Rest
Insider Buying Trends: Insider buying was prominent in Q4 2025, particularly in three stocks, with one standout due to its simple and effective technology that is in high demand in a rapidly growing industry.
Stock Performance and Institutional Activity: Insiders, including directors, have been actively purchasing shares, accumulating about 2% of the stock, while institutions own around 24%, indicating strong market interest despite a decline in stock prices.
Market Sentiment and Short Interest: Short interest remains high at nearly 7%, contributing to stock price declines, but analysts suggest a potential rebound with a significant upside forecast of 200% relative to consensus targets.
Investment Recommendations: Analysts rate the stock as a moderate buy, with a minimum upside of 12%, indicating a favorable long-term outlook as the market stabilizes and improves in revenue and earnings.
See More
Teva Pharmaceuticals' Request to Delay Paragard Lawsuit Trial Denied by Judge
- Trial Progress: A Georgia federal judge denied Teva Pharmaceuticals' request to delay the Paragard IUD lawsuit trial, ruling that it will proceed on January 20, 2024, marking the first trial in approximately 3,800 lawsuits, which could significantly impact the company's future legal liabilities and financial outlook.
- Litigation Context: Plaintiffs allege that the Paragard device can fracture during removal, leading to injuries and fertility complications, while Teva argues that FDA approval should preempt state law claims, indicating the company's urgency in its legal strategy to appeal for dismissal of the claims.
- Compliance Issues: The judge expressed concern over Teva's five-year delay in updating Paragard's warning labels as mandated by the FDA in 2010, suggesting potential intentionality that could undermine the court's trust in Teva and affect the case's outcome, thereby increasing the company's legal risks.
- Market Reaction: Teva's stock fell 0.21% to $32.72 in the latest trading session, reflecting market concerns about the upcoming trial and its potential financial implications, which may lead to decreased investor confidence.
See More
Boyar Research Unveils 2026's 'Forgotten Forty' Stocks with High Upside Potential
- Undervalued Stocks: Boyar Research's 'Forgotten Forty' list includes stocks like Uber and Airbnb, which are expected to outperform the market in the coming year, reflecting renewed investor interest in value stocks.
- Tax Law Impact: Atlanta Braves Holdings faces a tax law change effective in 2027 that limits deductions for top executives, potentially reducing profitability and prompting owner John Malone to consider selling the team to mitigate tax implications.
- Market Potential: Markel Group, dubbed the 'baby Berkshire', is under activist pressure to unlock value through share buybacks and operational improvements, with a current share price around $2,000 and an estimated worth of $3,100, indicating strong growth potential.
- Business Split Expectations: Cooper Companies, with a 25% market share in contact lenses, is facing calls for a split to optimize capital allocation, which analysts believe will enhance overall business performance and drive stock price increases.
See More
CooperVision Launches MyDay® MiSight® 1 Day Contact Lenses for Myopia Control
- Market Expansion: CooperVision is set to launch MyDay® MiSight® 1 Day contact lenses in the UK and select European markets, aiming to meet the growing demand for myopia control by combining ActivControl® technology with modern silicone hydrogel materials, which is expected to significantly enhance the company's market share in pediatric vision correction.
- Technological Innovation: The new lenses utilize ActivControl® technology, which has been shown to reduce myopia progression by approximately 50%, providing more effective vision protection for millions of children and further solidifying CooperVision's leadership position in the eye care industry.
- Enhanced User Experience: The design of MyDay® MiSight® 1 Day lenses includes corrective and therapeutic zones, ensuring users achieve clear vision while effectively controlling myopia progression, which is anticipated to boost customer satisfaction and brand loyalty.
- Strategic Commitment: CooperVision's Commercial Director, Debbie Olive, stated that the company is unwavering in its commitment to addressing myopia both scientifically and commercially; the launch of this new product not only reflects technological advancement but also a long-term commitment to children's eye health, expected to drive future sales growth.
See More
